55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent.
55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent.